drugset / Trial / NCT05574101
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to see if the combination of radiation therapy and cemiplimab immunotherapy is an effective treatment for people with locally advanced, unresectable CSCC.
Timeline
- Start
- 2022-10-06
- Primary completion
- 2026-10-06
- Completion
- 2026-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |